ICIs, particularly PD-1/PD-L1 inhibitors, have shown promise in untreated advanced or metastatic GC patients with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) (20), offering new hope for unresectable cases. This evidence concerns the gene CD274 and gastric cancer.